Avalo Therapeutics (AVTX) Peer Comparison

$19.23

$0.23 (1.21%)

As on 04-Sep-2026 16:35EDT

Market cap

$1,031 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

2.3

Div. Yield

0 %

Edit

	Avalo Therapeutics (AVTX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Market cap ($ Mln)	1,031	16,504	17,747	14,622	12,501
Revenue ($ Mln)	0	2,782	1,054	2,436	1,284
Net Profit ($ Mln)	-100.33	491.50	755.85	860.62	-325.10
Net Margin (%)	-170,055.93	17.67	71.69	35.33	-25.32
RoE (%)	-37.74	110.09	--	42.98	-57.72
Price to Earnings	--	34.72	20.93	18.56	--
Price-To-Book	2.31	38.18	10.51	7.95	23.94

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Avalo Therapeutics (AVTX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Operating Revenue	0.06	2,782.29	1,054.37	2,435.92	1,283.94
Cost of Revenue	10.02	1,982.07	103.47	85.67	109.42
Gross Profit	0.06	760.62	588.53	2,236.43	902.26
Operating Expenses	81.41	216.81	841.45	1,378.74	1,497.13
Operating Profit (EBIT)	-91.36	583.40	109.45	971.51	-322.62
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-100.16	598.92	101.11	1,035.47	-325.10
Provision for Tax	0.17	107.42	-654.74	174.84	0.00
Profit after Tax (Net Income)	-100.33	491.50	755.85	860.62	-325.10
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Avalo Therapeutics (AVTX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Shareholder's Funds	448.66	433.86	1,435.90	1,843.76	523.72
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	20.99	187.89	384.48	288.55	346.72
Current Liabilities	21.13	1,435.43	464.70	361.93	374.20
Total Liabilities	116.46	1,975.47	1,302.02	2,844.42	1,259.59

Assets ($ Mln)

	Avalo Therapeutics (AVTX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Non-Current Assets	82.85	1,006.90	895.24	1,243.41	45.47
Current Assets	407.93	1,050.29	1,389.84	1,250.82	1,199.18
Total Assets	116.46	1,975.47	1,302.02	2,844.42	1,259.59
Total Debt*	0.24	120.10	449.89	165.93	347.75
Net Current Assets	386.80	-385.14	925.52	888.90	824.98

Cashflow ($ Mln)

	Avalo Therapeutics (AVTX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Cash From Operating Activities	-51.46	713.22	51.77	884.27	-189.55
Cash Flow from Investing Activities	-81.72	-31.14	-8.15	350.44	32.32
Cash from Financing Activities	14.59	-860.39	34.89	-969.59	255.98
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Avalo Therapeutics (AVTX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
ROCE (%)	-71.44	53.56	-30.01	32.82	-31.49
ROE (%)	-37.74	110.09	163.18	42.98	-57.72
ROA (%)	-30.98	15.64	31.68	29.32	-22.97
EBIT Margin (%)	-169,766.10	21.13	5.73	31.04	-18.97
Net Margin (%)	-170,055.93	17.67	71.69	35.33	-25.32
Cash Profit Margin (%)	-1.56	0.00	0.00	0.00	0.00

Growth Ratios

	Avalo Therapeutics (AVTX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Revenue Growth (%)	-86.62	24.67	114.85	9.23	149.04
EBIT Growth (%)	-117.31	18.70	136.39	-3.99	9.16
Net Profit Growth (%)	-117.10	17.50	378.76	42.89	-15.32
EPS Growth (%)	-7.54	26.84	353.27	50.42	-0.64
Book Value Growth (%)	6.56	164.02	816.12	-0.70	-42.66

Valuation Ratios

	Avalo Therapeutics (AVTX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Price / Earnings	-4.30	36.06	-59.76	15.79	-45.32
Price / Book Value	4.05	35.44	-80.42	5.72	21.68
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-3.09	28.08	-121.54	12.44	-47.02
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Avalo Therapeutics (AVTX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Debt to Equity	0.00	0.00	0.27	0.00	0.65
Short term debt to equity ratio	0.00	0.00	0.05	0.00	0.00
Current Ratio	19.31	0.73	2.99	3.46	3.20
Quick Ratio	19.31	0.73	2.32	3.38	2.94
Interest Coverage	--	--	1.62	--	-9.32

Operating Efficiency Ratios

	Avalo Therapeutics (AVTX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Debtors to sales (%)	0.00	15.88	21.25	13.74	14.98
Asset Turnover	0.00	0.89	0.44	0.83	0.91
Receivable days	3,782.50	50.42	85.52	43.48	35.88
Inventory Days	--	--	1,056.70	96.17	354.23
Payable days	222.97	6.26	331.01	147.97	300.79
Cash Conversion Cycle	--	--	811.21	-8.32	89.33

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly